Read the latest updates from MitoRx Therapeutics

• • Publication
  • Posted 26 August, 2025

  Characterization of Myo4 in the murine diet-induced obesity model: a first-in-class anti-obesogenic muscle-preserving small molecule metabolic modulator

  Read More
• • In The Media
  • Posted 7 July, 2025

  New data backs Myo4 for obesity treatment – Drug Target Review

  Read More
• • In The Media
  • Posted 1 July, 2025

  MitoRx Takes Aim At GLP-1 Limitations – By Jo Shorthouse

  Read More
• • Press Release
  • Posted 23 June, 2025

  MitoRx Therapeutics presents data demonstrating restoration of insulin sensitivity, building on its muscle preserving weight loss approach in obesity

  Read More
• • Publication
  • Posted 20 June, 2025

  Myo4, a First-in-Class Anti-obesogenic and Muscle Preserving Small Molecule Metabolic Modulator

  Read More
• • Press Release
  • Posted 14 May, 2025

  MitoRx Therapeutics presents exciting new data showing weight loss with muscle preservation for novel small molecule Myo4 targeting obesity

  Read More
• • Publication
  • Posted 12 May, 2025

  The novel small molecule Myo4 normalises glycemic control, reduces weight/fat mass and prevents semaglutide-induced muscle remodelling in the murine diet-induced obesity model

  Read More
• • Press Release
  • Posted 1 May, 2025

  MitoRx Therapeutics appoints Xavier Jacq as CSO

  Read More
• • Press Release
  • Posted 9 January, 2025

  MitoRx Therapeutics Expands Leadership Team with Strategic Appointments of Chief Business Officer and Finance Director

  Read More
• • Press Release
  • Posted 10 October, 2024

  MitoRx Therapeutics Announces Publication Showing Mitochondrial Sulfide Donor AP39 Significantly Alleviates Obesity

  Read More